<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010388647</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010388647</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Impacts of Lisinopril and Lisinopril Plus Simvastatin on Erythrocyte and Plasma Arginase, Nitrite, and Nitrate in Hypertensive Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kosenko</surname><given-names>Elena</given-names></name>
<degrees>PhD, DSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Tikhonova</surname><given-names>Lyudmila</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Suslikov</surname><given-names>Alexander</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kaminsky</surname><given-names>Yury</given-names></name>
<degrees>PhD, DSc</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010388647">Institute of Theoretical and Experimental Biophysics, RAS, Pushchino, Russia (Dr Kosenko, Dr Kaminsky)</aff>
<aff id="aff2-0091270010388647">Belinsky State Teacher’s University, Penza, Russia (Ms Tikhonova)</aff>
<aff id="aff3-0091270010388647">Pushchino Research Center Hospital, RAS, Pushchino, Russia (Dr Suslikov)</aff>
<author-notes>
<corresp id="corresp1-0091270010388647">Yury Kaminsky, PhD, DSc, Institute of Theoretical and Experimental Biophysics, RAS, Institutskaya ul. 3, Pushchino, 142290 Russia; e-mail: <email>kaminsky@iteb.ru</email>.</corresp>
<fn fn-type="other" id="fn1-0091270010388647">
<p>All authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>109</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>8</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>10</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Angiotensin-converting enzyme inhibitors are effective at reducing blood pressure, whereas statins decrease plasma cholesterol, impeding atherosclerosis. The authors hypothesize that these medications may improve blood pressure by modifying the arginase–nitric oxide synthase system of erythrocytes. In this study, the effects of lisinopril alone versus lisinopril + simvastatin on erythrocyte and plasma arginase enzyme and nitric oxide metabolites are compared. Patients with atherosclerosis and hypertension are randomly assigned to receive lisinopril 10 to 20 mg/d or lisinopril 10 to 20 mg/d plus simvastatin 20 mg/d for 24 weeks. Higher arginase activity is observed in erythrocytes from 100% of patients and mainly recovered after 12 and 24 weeks of treatment with lisinopril or lisinopril + simvastatin. Plasma arginase activity is 3 orders of magnitude lower than erythrocyte arginase activity in all participants, suggesting a lack of its clinical significance. Both treatments cause the increase in plasma <inline-formula id="inline-formula1-0091270010388647">
<mml:math display="inline" id="math1-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula2-0091270010388647">
<mml:math display="inline" id="math2-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and <inline-formula id="inline-formula3-0091270010388647">
<mml:math display="inline" id="math3-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> + <inline-formula id="inline-formula4-0091270010388647">
<mml:math display="inline" id="math4-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> in 100% of patients. Erythrocyte <inline-formula id="inline-formula5-0091270010388647">
<mml:math display="inline" id="math5-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> + <inline-formula id="inline-formula6-0091270010388647">
<mml:math display="inline" id="math6-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration is greatly decreased in hypertensive patients but recovers after monotherapy and combined therapy. The results show for the first time that lisinopril monotherapy and combined lisinopril + simvastatin therapy exhibit pronounced and equipotential normalizing effects on erythrocyte arginase and nitric oxide synthase activities.</p>
</abstract>
<kwd-group>
<kwd>lisinopril</kwd>
<kwd>simvastatin</kwd>
<kwd>erythrocyte</kwd>
<kwd>arginase</kwd>
<kwd>nitrite/nitrate</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Angiotensin-converting enzyme (ACE) inhibitors such as lisinopril and HMG-CoA reductase inhibitors (statins) such as simvastatin are drugs in use today. ACE inhibitors are effective at reducing blood pressure (BP) in hypertension, whereas statins decrease plasma cholesterol, apparently counteracting atherosclerosis.</p>
<p>In patients receiving ACE inhibitors, BP is reduced, and in those receiving these medications plus statins, a greater reduction in BP occurs.<sup><xref ref-type="bibr" rid="bibr1-0091270010388647">1</xref>,<xref ref-type="bibr" rid="bibr2-0091270010388647">2</xref></sup> This evidence suggests a synergistic effect between the 2 drug types in hypertension.</p>
<p>Nitric oxide (NO) is an important regulator of BP.<sup><xref ref-type="bibr" rid="bibr3-0091270010388647">3</xref></sup> Endothelial production of NO is critical to the regulation of vascular responses, including vascular tone and regional blood flow. NO is a potent vasodilator. In NO deficiency, platelets and blood coagulation are activated.<sup><xref ref-type="bibr" rid="bibr4-0091270010388647">4</xref></sup></p>
<p>The synthesis of NO is catalyzed by the family of NO synthase (NOS; EC 1.14.13.39) enzymes, using arginine as a substrate. There are 3 NOS isoforms: neuronal, endothelial, and inducible. The inducible NOS catalyzes NO synthesis in all tissues and cells, including blood cells.<sup><xref ref-type="bibr" rid="bibr5-0091270010388647">5</xref>,<xref ref-type="bibr" rid="bibr6-0091270010388647">6</xref></sup> In red blood cells (RBCs), the endothelial NOS is expressed, stabilizing the membrane and regulating its deformability.<sup><xref ref-type="bibr" rid="bibr6-0091270010388647">6</xref></sup></p>
<p>Arginine, an NOS substrate, is also a substrate for arginase (EC 3.5.3.1). This enzyme catalyzes arginine hydrolysis to form citrulline and urea and is expressed mainly in hepatocytes.<sup><xref ref-type="bibr" rid="bibr7-0091270010388647">7</xref></sup> Lesser levels of arginase are found in a number of other tissues.<sup><xref ref-type="bibr" rid="bibr8-0091270010388647">8</xref>,<xref ref-type="bibr" rid="bibr9-0091270010388647">9</xref></sup> Its activity is detected in human and subhuman primate erythrocytes (RBCs).<sup><xref ref-type="bibr" rid="bibr10-0091270010388647">10</xref>,<xref ref-type="bibr" rid="bibr11-0091270010388647">11</xref></sup> Arginase deficiency and resulting hyperargininemia cause a clinical disorder characterized by indolent deterioration of the cortex and pyramidal tracts; progressive dementia and spasticity and short stature, usually beginning late in the second year of life<sup><xref ref-type="bibr" rid="bibr12-0091270010388647">12</xref></sup>; unsteadiness of gait; clumsiness of hands; tremors of the limbs and slurred speech; a mild hyperammonemia; hyperargininemia; and dibasic aminoaciduria in the fifth year.<sup><xref ref-type="bibr" rid="bibr13-0091270010388647">13</xref></sup></p>
<p>Under pathological conditions such as pulmonary hypertension<sup><xref ref-type="bibr" rid="bibr14-0091270010388647">14</xref></sup> and hemolytic anemia,<sup><xref ref-type="bibr" rid="bibr15-0091270010388647">15</xref></sup> the RBC arginase hyperactivation and subsequent release occur. The increase in plasma arginase activity is believed to lead to a limitation of arginine availability for NOS,<sup><xref ref-type="bibr" rid="bibr14-0091270010388647">14</xref></sup> NO plasma deficiency, and endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr15-0091270010388647">15</xref></sup> This evidence indicates that RBC arginase as well as endothelial cell arginase can be involved in the pathogenesis of vascular disease. However, it is unknown whether arginase activity changes and the relation between arginase activity and NO deficiency exist in RBCs and plasma from patients with affected cardiovascular systems.</p>
<p>NO is a highly unstable free radical and is oxidized rapidly to <inline-formula id="inline-formula7-0091270010388647">
<mml:math display="inline" id="math7-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula8-0091270010388647">
<mml:math display="inline" id="math8-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> in circulating blood. Blood levels of NO products, <inline-formula id="inline-formula9-0091270010388647">
<mml:math display="inline" id="math9-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula10-0091270010388647">
<mml:math display="inline" id="math10-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, serve often as clinically available indexes of endothelial NOS activity and indirect measures of NO levels.<sup><xref ref-type="bibr" rid="bibr16-0091270010388647">16</xref>,<xref ref-type="bibr" rid="bibr17-0091270010388647">17</xref></sup> Because of a number of potential biological functions, blood <inline-formula id="inline-formula11-0091270010388647">
<mml:math display="inline" id="math11-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentrations are thought to be of particular importance.<sup><xref ref-type="bibr" rid="bibr18-0091270010388647">18</xref></sup> High <inline-formula id="inline-formula12-0091270010388647">
<mml:math display="inline" id="math12-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> levels can cause intoxication and have a fatal outcome by binding with hemoglobin (Hb) to form MetHb, which is not capable of transferring oxygen. Nutritive <inline-formula id="inline-formula13-0091270010388647">
<mml:math display="inline" id="math13-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> is an intestinal carcinogen<sup><xref ref-type="bibr" rid="bibr19-0091270010388647">19</xref></sup> and may be a cause of chronic obstructive pulmonary disease.<sup><xref ref-type="bibr" rid="bibr20-0091270010388647">20</xref></sup> However, little is known about NO transformation into its metabolites in hypertensive patients before and during treatment.</p>
<p>NO<sub>x</sub>, the sum of <inline-formula id="inline-formula14-0091270010388647">
<mml:math display="inline" id="math14-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula15-0091270010388647">
<mml:math display="inline" id="math15-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentrations, is used often for a valuation of NO bioavailability in vivo.</p>
<p>There are no data available on the homeostasis and the effects of statins and ACE inhibitors on RBCs and plasma arginase/NO synthase systems in hypertensive patients. We hypothesize that these medications may improve BP by modifying the arginase/NO synthase system of RBCs regulating vasodilation. Therefore, the aim of this study was to determine whether the treatments with lisinopril and simvastatin affect RBC and plasma arginase activity as well as <inline-formula id="inline-formula16-0091270010388647">
<mml:math display="inline" id="math16-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula17-0091270010388647">
<mml:math display="inline" id="math17-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> levels in hypertensive, atherosclerotic patients.</p>
<sec id="section1-0091270010388647" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010388647">
<title>Patients</title>
<p>Twenty-nine patients aged 44 to 72 years (mean, 58 years) with essential hypertension stage I or II and moderate hyperlipidemia were enrolled in the investigation from October 2007 to April 2008 and followed up for 24 weeks. Inclusion criteria were the symptoms of peripheral artery atherosclerosis; total serum cholesterol, low-density lipoprotein (LDL) cholesterol, plasma triglycerides, and creatinine screening levels of not more than 6.5 mM (250 mg/dL), 4.2 mM (160 mg/dL), 4 mM (400 mg/dL), and 0.2 mM, respectively; plasma aspartate and alanine aminotransferase levels of not more than twice the upper limit of normal range; and plasma creatine kinase activity of &lt;3 times the upper limit of normal range.</p>
<p>Exclusion criteria were ischemic heart disease; secondary hyperlipidemia; clinically pronounced liver, kidney, or heart failure; acute infections; hypolipidemic or ACE inhibitor therapy for at least 4 weeks before the investigation; and lisinopril and simvastatin intolerance. All patients agreed to participate in this study and to receive continuous therapies for 24 weeks.</p>
</sec>
<sec id="section3-0091270010388647">
<title>Study Design</title>
<p>Patients were randomized to receive once-daily treatment with lisinopril 10 to 20 mg (lisinopril group of 14 outpatients, 6 women and 8 men) or lisinopril 10 to 20 mg and simvastatin 20 mg (lisinopril + simvastatin group, 7 women and 8 men) for 24 weeks.</p>
<p>The study is a collaborative effort of academic research and medical centers. It was carried out in parallel with the multicenter, open, randomized, comparative perspective investigation (ELASTICA) in an independent manner as described previously.<sup><xref ref-type="bibr" rid="bibr21-0091270010388647">21</xref></sup> Evaluations were performed at baseline and after 12 and 24 weeks of treatment.</p>
<p>The investigation conforms with the principles outlined in the Declaration of Helsinki and was approved by the institutional review boards at the Medical Center and Institute of Theoretical and Experimental Biophysics before its implementation.</p>
</sec>
<sec id="section4-0091270010388647">
<title>Materials</title>
<p>Lisinopril and simvastatin were from Gedeon Richter (Budapest, Hungary). Sodium citrate, glucose, nitrate reductase, L-arginine, Tris, Griess reagent, and saponin were from Sigma Chemical Co (St Louis, Missouri). Other chemicals were commercially available.</p>
</sec>
<sec id="section5-0091270010388647">
<title>Procedures</title>
<p>Venous blood collections were carried out between 08:00 and 09:00 hours after an overnight fast at baseline and 12 and 24 weeks of the daily monotherapy and combined therapy. Thus, in the present study, the same patients were assayed before and after treatment, serving as self-controls. Another group of 10 young healthy volunteers served as additional controls to hypertensive patients (the control group).</p>
<p>Clinical and standard biochemical analyses were performed immediately (within 30 minutes) after blood collection in the Hospital at the Pushchino Research Center, and preparation and biochemical analysis of RBCs and plasma were performed at the Institute of Theoretical and Experimental Biophysics, in the Laboratory of Metabolic Modeling and Bioinformatics.</p>
<p>Each RBC preparation was obtained from the blood of 1 patient without mixing different blood samples essentially as described previously.<sup><xref ref-type="bibr" rid="bibr21-0091270010388647">21</xref>,<xref ref-type="bibr" rid="bibr22-0091270010388647">22</xref></sup> RBC suspensions were stored at 4°C for no longer than 24 hours.</p>
</sec>
<sec id="section6-0091270010388647">
<title>Arginase Activity Measurement</title>
<p>To activate arginase, 0.1 mL of thawed RBC suspension was mixed with 0.1 mL of 100 mM glycyl-glycine buffer (pH 8.5) containing 20 mM MnCl<sub>2</sub> and incubated for 10 minutes at 55°C. The arginase reaction was initiated by addition of 25 mM arginine in 0.2 mL of the buffer. Arginine hydrolysis proceeded for 15 minutes at 37°C. The reaction was stopped by 0.1 mL of 15% HClO<sub>4</sub> addition. After centrifugation (10 000 <italic>g</italic> for 5 minutes at +4°C), the supernatant was neutralized with dry KНСО<sub>3</sub> and 30% KОН to a final pH of 7. The potassium perchlorate residue was removed by centrifugation.</p>
<p>Arginase activity was estimated by urea formed and expressed as nkat/g Hb. The urea concentration in the clear supernatant was determined spectrophotometrically using the enzymatic method<sup><xref ref-type="bibr" rid="bibr23-0091270010388647">23</xref></sup> by the concentration of ammonia generated by urease via urea hydrolysis. Plasma arginase activity was expressed as nkat/L.</p>
</sec>
<sec id="section7-0091270010388647">
<title>Measurements of Plasma and RBC Concentrations of <inline-formula id="inline-formula18-0091270010388647">
<mml:math display="inline" id="math18-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula19-0091270010388647">
<mml:math display="inline" id="math19-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula></title>
<p>Plasma <inline-formula id="inline-formula20-0091270010388647">
<mml:math display="inline" id="math20-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula21-0091270010388647">
<mml:math display="inline" id="math21-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentrations were assayed using the spectrophotometric Griess method<sup><xref ref-type="bibr" rid="bibr24-0091270010388647">24</xref>,<xref ref-type="bibr" rid="bibr25-0091270010388647">25</xref></sup> with some modifications. Plasma was separated from RBCs by centrifugation of the blood at 10 000 <italic>g</italic> for 1 minute at +4°C and stored at −20°C. Then plasma was diluted 2- to 4-fold with distilled water and deproteinized with the cold 0.6N НClO<sub>4</sub>/80% ethanol mixture. Following centrifugation at 10 000 <italic>g</italic> for 5 minutes at +4°C, the supernatant was neutralized with dry KНСО<sub>3</sub> and 30% KОН and repeatedly centrifuged. The second supernatant was mixed 1:1 with Griess reagent (1% sulfanilamide and 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride in 5% H<sub>3</sub>PO<sub>4</sub>) and incubated for 30 minutes in the dark, and the absorption at 540 nm was measured. The control sample was prepared with Griess reagent containing no N-naphthyl-ethylenediamine. Sodium nitrite (NaNO<sub>2</sub>, 0-100 µM) was used to generate a standard curve for quantification of <inline-formula id="inline-formula22-0091270010388647">
<mml:math display="inline" id="math22-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration.</p>
<p>Plasma <inline-formula id="inline-formula23-0091270010388647">
<mml:math display="inline" id="math23-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration was measured after enzymatic conversion of plasma <inline-formula id="inline-formula24-0091270010388647">
<mml:math display="inline" id="math24-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> to <inline-formula id="inline-formula25-0091270010388647">
<mml:math display="inline" id="math25-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> by nitrate reductase (EC 1.9.6.1).<sup><xref ref-type="bibr" rid="bibr26-0091270010388647">26</xref></sup> Diluted plasma was incubated with nitrate reductase (0.02 IU in a total volume of 0.1 mL) and 0.08 mM nicotinamide adenine dinucleotide phosphate (NADPH) in 20 mM Tris buffer (pH 7.6) at 25°C. Thirty minutes later, samples were deproteinized and neutralized. The NO<sub>x</sub> concentration was measured in the supernatant, as described above. The <inline-formula id="inline-formula26-0091270010388647">
<mml:math display="inline" id="math26-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration was calculated by subtraction of <inline-formula id="inline-formula27-0091270010388647">
<mml:math display="inline" id="math27-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> from NO<sub>x</sub>.</p>
<p>To prepare a hemolysate, 0.25 mL of freshly isolated RBC suspension was incubated in 0.5 mL of 10 mM Tris buffer (pH 7.4) containing 0.2% saponin for 10 minutes, deproteinized, and neutralized. In the hemolysate, NO<sub>x</sub> was determined.</p>
</sec>
<sec id="section8-0091270010388647">
<title>Statistical Analysis</title>
<p>Statistical analyses were performed using the Prism 4.03 statistical program (GraphPad, San Diego, California). Differences between groups were analyzed with the Student <italic>t</italic> test.</p>
</sec>
</sec>
<sec id="section9-0091270010388647" sec-type="results|discussion">
<title>Results and Discussion</title>
<p><xref ref-type="fig" rid="fig1-0091270010388647">Figure 1</xref> shows arginase activity in RBCs from controls and patients before and after 12 and 24 weeks of treatment with lisinopril or lisinopril + simvastatin. There was a statistically significant increase in RBC arginase activity in hypertensive patients from the lisinopril group (baseline, by 18%; <italic>P</italic> &lt; .05), when compared with that in normotensive controls. RBC arginase activity in hypertensive patients tended to decrease (<italic>P</italic> &gt; .07) and mainly normalized after 12 and 24 weeks of treatment with lisinopril.</p>
<fig id="fig1-0091270010388647" position="float">
<label>Figure 1.</label>
<caption><p>Red blood cell (RBC) arginase activity in normotensive controls and hypertensive patients. Patients received lisinopril or lisinopril + simvastatin daily for 12 and 24 weeks. Data are presented as mean ± SEM for <italic>n</italic> = 10 to 15. *<italic>P</italic> &lt; .05 vs control.</p></caption>
<graphic xlink:href="10.1177_0091270010388647-fig1.tif"/>
</fig>
<p>Increased RBC arginase activity was observed in 100% of the patients, indicating the communion of the effects. The second trend was toward lower RBC arginase activity in 100% of hypertensive patients in both lisinopril subgroups (12 and 24 weeks) than baseline levels (<italic>P</italic> &lt; .002). Two trends suggest the direct connection between RBC arginase activity and hypertension and the direct effect of lisinopril on this connection.</p>
<p>The same results were observed in patients receiving lisinopril + simvastatin (<xref ref-type="fig" rid="fig1-0091270010388647">Figure 1</xref>). Higher arginase activity (by 19%; <italic>P</italic> &lt; .05) was observed in RBCs from hypertensive patients when compared with RBCs from normotensive controls. In 100% of the patients, RBC arginase activity was decreased (by 14%; <italic>P</italic> = .002) and mainly restored to the control level after 12 and 24 weeks of treatment with lisinopril + simvastatin. The trend suggests the direct effect of lisinopril + simvastatin on the connection between RBC arginase activity and hypertension.</p>
<p>There was no difference between the lisinopril and lisinopril + simvastatin groups for RBC arginase activity at any period of therapy (<xref ref-type="fig" rid="fig1-0091270010388647">Figure 1</xref>). Hence, it appears that simvastatin does not affect arginase activity and the lisinopril effect.</p>
<p>Plasma arginase activity was 36.7 ± 7.2 nkat/L (range, 16.2-71.1 nkat/L), 3 orders of magnitude lower than RBC arginase activity (as referred to 1L of packed volume) in 100% of the patients. Results are very similar to other literature data.<sup><xref ref-type="bibr" rid="bibr14-0091270010388647">14</xref></sup> These figures correspond to changes of plasma arginine concentrations, a maximum of 2 nmol/min per 1 mL plasma, whereas their steady-state concentrations were in the millimolar range, suggesting a lack of biological significance.</p>
<p>Observed plasma/RBC distribution of arginase can be evidence that arginase is not a “constitutive” plasma enzyme but arises in plasma as a result of cell damage (eg, RBC hemolysis).</p>
<p>Plasma arginase activity in patients was 84.7 nkat/L (range, 32.2-109.2 nkat/L), 130% higher than in controls, implicating at least 2.3-fold more RBCs damaged in hypertension.</p>
<p>The lisinopril effect on plasma arginase was not univocal. In 6 patients, initially elevated plasma arginase activity was reduced by 13% to 47% after 12 and 24 weeks of monotherapy but did not achieve the control levels. In 2 patients, lisinopril therapy resulted in a 25% to 30% increase in plasma arginase activity compared with baseline, and 6 other patients did not show any change in plasma arginase. On average for 14 patients, plasma arginase activity changed insignificantly after 12 and 24 weeks of lisinopril treatment (<xref ref-type="fig" rid="fig2-0091270010388647">Figure 2</xref>).</p>
<fig id="fig2-0091270010388647" position="float">
<label>Figure 2.</label>
<caption><p>Plasma arginase activity in normotensive controls and hypertensive patients. Patients received lisinopril or lisinopril + simvastatin daily for 12 and 24 weeks. Data are presented as mean ± SEM for <italic>n</italic> = 10 to 15. ***<italic>P</italic> &lt; .0001 vs control.</p></caption>
<graphic xlink:href="10.1177_0091270010388647-fig2.tif"/>
</fig>
<p>The same results, qualitatively and quantitatively, were observed in patients receiving lisinopril + simvastatin (<xref ref-type="fig" rid="fig2-0091270010388647">Figure 2</xref>).</p>
<p>In most patients (10 of 14; 1 patient was excluded from plasma arginase determination) who received lisinopril + simvastatin for 24 weeks, a decrease in plasma arginase activity, elevated initially, occurred, although combined therapy had a lower efficiency (4%-30%) than monotherapy (13%-47%). Four patients showed increased plasma arginase activity (by 3%-15%) after combined therapy compared with baseline. On average, for 14 hypertensive persons, lisinopril + simvastatin treatment changed plasma arginase activity insignificantly.</p>
<p>The similarity of patterns of arginase activity in RBCs and plasma (<xref ref-type="fig" rid="fig1-0091270010388647">Figures 1</xref> and <xref ref-type="fig" rid="fig2-0091270010388647">2</xref>) supports an assumption that plasma arginase is the in vivo product of lysed RBCs. Although Gladwin<sup><xref ref-type="bibr" rid="bibr15-0091270010388647">15</xref></sup> and Morris<sup><xref ref-type="bibr" rid="bibr27-0091270010388647">27</xref></sup> suggested that released RBC arginase disturbs arginine metabolism in plasma, it is unlikely that low plasma arginase activity could significantly alter the plasma arginine concentration and hence have any clinical and probably biological significance.<sup><xref ref-type="bibr" rid="bibr28-0091270010388647">28</xref></sup></p>
<p>Plasma <inline-formula id="inline-formula28-0091270010388647">
<mml:math display="inline" id="math28-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration in healthy controls was 6.5 ± 1.1 µmol/L (range, 2.2-10.9 µmol/L), <inline-formula id="inline-formula29-0091270010388647">
<mml:math display="inline" id="math29-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration was 25.6 ± 1.4 µmol/L (17.8-29 µmol/L), and NO<sub>x</sub> concentration was 32.1 ± 1.4 µmol/L (22.1-39 µmol/L). These results are similar to those obtained by other authors.<sup><xref ref-type="bibr" rid="bibr24-0091270010388647">24</xref>,<xref ref-type="bibr" rid="bibr29-0091270010388647">29</xref>-<xref ref-type="bibr" rid="bibr31-0091270010388647">31</xref></sup></p>
<p>Plasma baseline <inline-formula id="inline-formula30-0091270010388647">
<mml:math display="inline" id="math30-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula31-0091270010388647">
<mml:math display="inline" id="math31-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> in patients did not differ from control levels (<italic>P</italic> ≥ .12; <xref ref-type="fig" rid="fig3-0091270010388647">Figure 3</xref>), whereas the NO<sub>x</sub> concentration was slightly but significantly lower (by 13.8%; <italic>P</italic> = .0318) compared with controls. After 12 and 24 weeks of treatment with lisinopril, plasma <inline-formula id="inline-formula32-0091270010388647">
<mml:math display="inline" id="math32-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> did not change, and plasma <inline-formula id="inline-formula33-0091270010388647">
<mml:math display="inline" id="math33-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and NO<sub>x</sub> increased significantly by 23% to 31% (<italic>P</italic> ≤ .01) in comparison with baseline.</p>
<fig id="fig3-0091270010388647" position="float">
<label>Figure 3.</label>
<caption>
<p>Plasma <inline-formula id="inline-formula34-0091270010388647">
<mml:math display="inline" id="math34-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula35-0091270010388647">
<mml:math display="inline" id="math35-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in controls and patients who received lisinopril or lisinopril + simvastatin daily for 12 and 24 weeks. Data are expressed as µmol/L and presented as mean ± SEM for <italic>n</italic> = 10 to 15. *<italic>P</italic> &lt; .05, **<italic>P</italic> &lt; .001 vs control.</p>
</caption>
<graphic xlink:href="10.1177_0091270010388647-fig3.tif"/>
</fig>
<p>Plasma <inline-formula id="inline-formula36-0091270010388647">
<mml:math display="inline" id="math36-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula37-0091270010388647">
<mml:math display="inline" id="math37-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in patients who received lisinopril for 12 and 24 weeks did not differ from those in normotensive controls (.93 &gt; <italic>P</italic> &gt; .06; except that <inline-formula id="inline-formula38-0091270010388647">
<mml:math display="inline" id="math38-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> levels at 24 weeks were significantly higher, <italic>P</italic> = .04). Monotherapy caused the increase in plasma <inline-formula id="inline-formula39-0091270010388647">
<mml:math display="inline" id="math39-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula40-0091270010388647">
<mml:math display="inline" id="math40-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in 100% of patients. These figures mean that plasma NO homeostasis was disturbed in hypertensive patients and was mainly recovered after 24 weeks of lisinopril therapy.</p>
<p>Combined lisinopril + simvastatin treatment for 12 weeks did not change plasma <inline-formula id="inline-formula41-0091270010388647">
<mml:math display="inline" id="math41-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentration in patients but induced a significant increase in <inline-formula id="inline-formula42-0091270010388647">
<mml:math display="inline" id="math42-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and NO<sub>x</sub> concentrations by 28% and 24% (<italic>P</italic> &lt; .01), respectively, to control levels (<xref ref-type="fig" rid="fig3-0091270010388647">Figure 3</xref>).</p>
<p>The most pronounced effects of combined treatment were observed after 24 weeks: <inline-formula id="inline-formula43-0091270010388647">
<mml:math display="inline" id="math43-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula44-0091270010388647">
<mml:math display="inline" id="math44-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations increased significantly by 52% to 57% (<italic>P</italic> &lt; .05) in comparison with baseline.</p>
<p>Plasma <inline-formula id="inline-formula45-0091270010388647">
<mml:math display="inline" id="math45-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula46-0091270010388647">
<mml:math display="inline" id="math46-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in patients who received lisinopril + simvastatin for 12 weeks did not differ from normotensive controls (.95 &gt; <italic>P</italic> &gt; .35). Combined therapy for 24 weeks led to increases in plasma <inline-formula id="inline-formula47-0091270010388647">
<mml:math display="inline" id="math47-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula48-0091270010388647">
<mml:math display="inline" id="math48-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in 100% of patients. Taken together, these findings suggest that plasma NO homeostasis is disturbed in hypertensive patients and mainly recovered after 12 weeks of lisinopril + simvastatin treatment. After 24 weeks of combined therapy, plasma <inline-formula id="inline-formula49-0091270010388647">
<mml:math display="inline" id="math49-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and NO<sub>x</sub> concentrations were significantly higher than those in controls (<italic>P</italic> &lt; .001), suggesting simvastatin-induced overactivation of the NO synthase system. The latter effect of simvastatin is not known and observed for the first time. However, our suggestion of overactivation of endothelial NO synthase in RBCs by statins was confirmed by the literature data. Overexpression of the NO synthase gene in endothelial cells treated with simvastatin was recently reported.<sup><xref ref-type="bibr" rid="bibr32-0091270010388647">32</xref></sup> Earlier, Feron et al<sup><xref ref-type="bibr" rid="bibr33-0091270010388647">33</xref></sup> showed that another statin, atorvastatin, stimulated endothelial NO synthase activity and NO generation in cultured endothelial cells.</p>
<p>The steady-state plasma NO<sub>x</sub> concentrations are known to correlate with whole-blood NO<sub>x</sub> and RBC NO<sub>x</sub> concentrations.<sup><xref ref-type="bibr" rid="bibr34-0091270010388647">34</xref>,<xref ref-type="bibr" rid="bibr35-0091270010388647">35</xref></sup> Moreover, there is an equilibrium between plasma NO<sub>x</sub> and RBC NO<sub>x</sub>,<sup><xref ref-type="bibr" rid="bibr35-0091270010388647">35</xref></sup> whereas plasma <inline-formula id="inline-formula50-0091270010388647">
<mml:math display="inline" id="math50-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula51-0091270010388647">
<mml:math display="inline" id="math51-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentrations correlate with plasma NO<sub>x</sub> (<xref ref-type="fig" rid="fig3-0091270010388647">Figures 3</xref> and <xref ref-type="fig" rid="fig4-0091270010388647">4</xref>). Therefore, we measured only NO<sub>x</sub> in RBCs.</p>
<fig id="fig4-0091270010388647" position="float">
<label>Figure 4.</label>
<caption><p>Red blood cell (RBC) NO<sub>x</sub> concentration in controls and patients. Patients received lisinopril or lisinopril + simvastatin daily for 12 and 24 weeks. Data are expressed as µmol/g Hb and presented as mean ± SEM for <italic>n</italic> = 10 to 15. **<italic>P</italic> &lt; .01 vs control.</p></caption>
<graphic xlink:href="10.1177_0091270010388647-fig4.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig4-0091270010388647">Figure 4</xref> shows RBC NO<sub>x</sub> levels in controls and patients receiving lisinopril or lisinopril + simvastatin for 12 and 24 weeks. In healthy controls, RBC NO<sub>x</sub> concentration was about 16 µmol/L of packed cells, in accordance with the literature.<sup><xref ref-type="bibr" rid="bibr34-0091270010388647">34</xref>,<xref ref-type="bibr" rid="bibr35-0091270010388647">35</xref></sup> It was significantly lower (by 32%; <italic>P</italic> = .0059) in untreated patients compared with controls. The lisinopril treatment led to the 42% to 47% increase in RBC NO<sub>x</sub> concentration after 12 and 24 weeks; posttreatment RBC NO<sub>x</sub> concentrations were at the control levels (<xref ref-type="fig" rid="fig4-0091270010388647">Figure 4</xref>).</p>
<p>Combined lisinopril + simvastatin therapy affected the RBC NO<sub>x</sub> concentration in a pattern virtually identical to that of lisinopril alone (<xref ref-type="fig" rid="fig4-0091270010388647">Figure 4</xref>). However, the 2 drugs exerted a stronger effect. After 12 and 24 weeks of combined therapy, RBC NO<sub>x</sub> concentrations were increased by as much as 61% (<italic>P</italic> = .008) and 74% (<italic>P</italic> &lt; .0001), respectively, in comparison with baseline and were statistically indistinguishable (<italic>P</italic> = .0517) from control values. Again, these results confirmed the suggestion of activation of endothelial NO synthase in RBCs by simvastatin.</p>
<p>In the preliminary report, we have showed that only combined lisinopril + simvastatin treatment, not lisinopril alone, induced decreases in plasma total cholesterol and LDL cholesterol after 4 to 24 weeks, demonstrating the specific cholesterol-lowering effect of simvastatin with no effect of lisinopril. Both treatments reduced systolic and diastolic BP evenly, demonstrating the specific BP-lowering effect of lisinopril with no effect of simvastatin.<sup><xref ref-type="bibr" rid="bibr21-0091270010388647">21</xref></sup> Arginase represents a promising novel target for pharmacological intervention in essential hypertension.<sup><xref ref-type="bibr" rid="bibr36-0091270010388647">36</xref></sup> Together, these and present results suggest that the beneficial impacts of lisinopril and the lisinopril + simvastatin combination on BP are mediated, at least in part, by decreasing arginase activity and increasing <inline-formula id="inline-formula52-0091270010388647">
<mml:math display="inline" id="math52-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula53-0091270010388647">
<mml:math display="inline" id="math53-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> concentrations (ie, elevation of NO synthase activity) in RBCs. Both treatments may protect RBCs as well as endothelial cells from adverse events associated with hypertension. Therefore, we assume that the effects of lisinopril and the lisinopril + simvastatin combination on BP (and cholesterol levels) are secondary to their action on RBC arginase and NO synthase enzymes in hypertensive, atherosclerotic patients.</p>
<p>In summary, in peripheral artery hypertension, RBC arginase activity increased significantly. In all 29 hypertensive patients studied, antihypertensive monotherapy with lisinopril and combined antihypertensive and hypolipidemic therapy with lisinopril + simvastatin caused the decrease in RBC arginase activity to the normotensive control level. Plasma arginase was 3 orders of magnitude less active than the RBC enzyme and seemed to have no clinical significance. Plasma <inline-formula id="inline-formula54-0091270010388647">
<mml:math display="inline" id="math54-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula55-0091270010388647">
<mml:math display="inline" id="math55-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations in hypertensive patients were lower than those in normotensive controls. Treatment with lisinopril or lisinopril + simvastatin led to the increase in plasma <inline-formula id="inline-formula56-0091270010388647">
<mml:math display="inline" id="math56-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>2</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula57-0091270010388647">
<mml:math display="inline" id="math57-0091270010388647">
<mml:mrow>
<mml:mtext>N</mml:mtext>
<mml:msubsup>
<mml:mtext>O</mml:mtext>
<mml:mn>3</mml:mn>
<mml:mo>−</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, and NO<sub>x</sub> concentrations. RBC NO<sub>x</sub> concentration was sharply reduced in hypertension but wholly recovered after 12 to 24 weeks of monotherapy and combined therapy. The result suggests that there is an inverse link between arginase and NO synthase activities in RBCs, but this relation disappears after both monotherapy and combined therapy. Our data show for the first time that in patients with peripheral artery atherosclerosis and moderate hypertension, treatment with lisi-nopril or lisinopril + simvastatin is associated with the pronounced and equipotent changes of RBC and plasma arginase and NO synthase activities.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supported-by">
<p>This work was not supported by any grant.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The authors have nothing to disclose.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010388647">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spósito</surname><given-names>AC</given-names></name>
<name><surname>Mansur</surname><given-names>AP</given-names></name>
<name><surname>Coelho</surname><given-names>OR</given-names></name>
<name><surname>Nicolau</surname><given-names>JC</given-names></name>
<name><surname>Ramires</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)</article-title>. <source>Am J Cardiol</source>. <year>1999</year>;<volume>83</volume>:<fpage>1497</fpage>-<lpage>1499</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010388647">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ledingham</surname><given-names>JM</given-names></name>
<name><surname>Laverty</surname><given-names>R</given-names></name>
</person-group>. <article-title>Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2005</year>;<volume>32</volume>:<fpage>76</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010388647">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Das</surname><given-names>S</given-names></name>
<name><surname>Kumar</surname><given-names>KN</given-names></name>
</person-group>. <article-title>Nitric oxide: its identity and role in blood pressure control</article-title>. <source>Life Sci</source>. <year>1995</year>;<volume>57</volume>:<fpage>1547</fpage>-<lpage>1556</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010388647">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moncada</surname><given-names>S</given-names></name>
<name><surname>Higgs</surname><given-names>A</given-names></name>
</person-group>. <article-title>The L-arginine–nitric oxide pathway</article-title>. <source>N Engl J Med</source>. <year>1993</year>;<volume>329</volume>:<fpage>2002</fpage>-<lpage>2012</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010388647">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charles</surname><given-names>IG</given-names></name>
<name><surname>Palmer</surname><given-names>RMJ</given-names></name>
<name><surname>Hickery</surname><given-names>MS</given-names></name>
<etal/></person-group>. <article-title>Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1993</year>;<volume>90</volume>:<fpage>11419</fpage>-<lpage>11423</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010388647">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleinbongard</surname><given-names>P</given-names></name>
<name><surname>Schulz</surname><given-names>R</given-names></name>
<name><surname>Rassaf</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Red blood cells express a functional endothelial nitric oxide synthase</article-title>. <source>Blood</source>. <year>2006</year>;<volume>107</volume>:<fpage>2943</fpage>-<lpage>2951</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010388647">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>SM</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Arginine metabolism: boundaries of our knowledge</article-title>. <source>J Nutr</source>. <year>2007</year>;<volume>137</volume>(<issue>suppl 2</issue>):<fpage>1602S</fpage>-<lpage>1609S</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010388647">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Brusilow</surname><given-names>SW</given-names></name>
<name><surname>Horwich</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Urea cycle enzymes</article-title>. In: <person-group person-group-type="editor">
<name><surname>Scriver</surname><given-names>CR</given-names></name>
<name><surname>Beaudet</surname><given-names>AL</given-names></name>
<name><surname>Sly</surname><given-names>WS</given-names></name>
<name><surname>Valle</surname><given-names>D</given-names></name>
</person-group>, eds. <source>The Metabolic and Molecular Bases of Inherited Diseases</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>1995</year>:<fpage>621</fpage>-<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010388647">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jenkinson</surname><given-names>CP</given-names></name>
<name><surname>Grody</surname><given-names>WW</given-names></name>
<name><surname>Cederbaum</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Comparative properties of arginases</article-title>. <source>Comp Biochem Physiol</source>. <year>1996</year>;<volume>114B</volume>:<fpage>107</fpage>-<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010388647">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>PS</given-names></name>
<name><surname>Iyer</surname><given-names>RK</given-names></name>
<name><surname>Lu</surname><given-names>KV</given-names></name>
<etal/></person-group>. <article-title>Expression of the liver form of arginase in erythrocytes</article-title>. <source>Mol Genet Metab</source>. <year>2002</year>;<volume>76</volume>:<fpage>100</fpage>-<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010388647">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berüter</surname><given-names>J</given-names></name>
<name><surname>Colombo</surname><given-names>JP</given-names></name>
<name><surname>Bachmann</surname><given-names>C</given-names></name>
</person-group>. <article-title>Purification and properties of arginase from human liver and erythrocytes</article-title>. <source>Biochem J</source>. <year>1978</year>;<volume>175</volume>:<fpage>449</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010388647">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iyer</surname><given-names>R</given-names></name>
<name><surname>Jenkinson</surname><given-names>CP</given-names></name>
<name><surname>Vockley</surname><given-names>JG</given-names></name>
<name><surname>Kern</surname><given-names>RM</given-names></name>
<name><surname>Grody</surname><given-names>WW</given-names></name>
<name><surname>Cederbaum</surname><given-names>S</given-names></name>
</person-group>. <article-title>The human arginases and arginase deficiency</article-title>. <source>J Inher Metab Dis</source>. <year>1998</year>;<volume>21</volume>(<issue>suppl 1</issue>):<fpage>86</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010388647">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christopher</surname><given-names>R</given-names></name>
<name><surname>Rajivnath</surname><given-names>V</given-names></name>
<name><surname>Shetty</surname><given-names>KT</given-names></name>
</person-group>. <article-title>Arginase deficiency</article-title>. <source>Indian J Pediatr</source>. <year>1997</year>;<volume>64</volume>:<fpage>266</fpage>-<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010388647">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>CR</given-names></name>
<name><surname>Kato</surname><given-names>GJ</given-names></name>
<name><surname>Poljakovic</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>:<fpage>81</fpage>-<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010388647">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gladwin</surname><given-names>MT</given-names></name>
</person-group>. <article-title>Role of the red blood cell in nitric oxide homeostasis and hypoxic vasodilation</article-title>. <source>Adv Exp Med Biol</source>. <year>2006</year>;<volume>588</volume>:<fpage>189</fpage>-<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010388647">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lauer</surname><given-names>T</given-names></name>
<name><surname>Preik</surname><given-names>M</given-names></name>
<name><surname>Rassaf</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2001</year>;<volume>98</volume>:<fpage>12814</fpage>-<lpage>12819</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010388647">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleinbongard</surname><given-names>P</given-names></name>
<name><surname>Dejam</surname><given-names>A</given-names></name>
<name><surname>Lauer</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals</article-title>. <source>Free Radic Biol Med</source>. <year>2003</year>;<volume>35</volume>:<fpage>790</fpage>-<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010388647">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grau</surname><given-names>M</given-names></name>
<name><surname>Hendgen-Cotta</surname><given-names>UB</given-names></name>
<name><surname>Brouzos</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Recent methodological advances in the analysis of nitrite in the human circulation: nitrite as a biochemical parameter of the L-arginine/NO pathway</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>. <year>2007</year>;<volume>851</volume>:<fpage>106</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010388647">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Susanna</surname><given-names>AW</given-names></name>
<name><surname>Larsson</surname><given-names>C</given-names></name>
</person-group>. <article-title>Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies</article-title>. <source>Int J Cancer</source>. <year>2006</year>;<volume>119</volume>:<fpage>2657</fpage>-<lpage>2664</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010388647">
<label>20.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Hitti</surname><given-names>M</given-names></name>
</person-group>. <article-title>Eating cured meats makes chronic obstructive pulmonary disease more likely, study shows. WebMD Medical News</article-title>. <access-date>April 17, 2007</access-date>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.webmd.com/lung/copd/news/20070417/study-copd-cured-meats-may-be-linked">http://www.webmd.com/lung/copd/news/20070417/study-copd-cured-meats-may-be-linked</ext-link></comment></citation>
</ref>
<ref id="bibr21-0091270010388647">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaminsky</surname><given-names>Y</given-names></name>
<name><surname>Suslikov</surname><given-names>A</given-names></name>
<name><surname>Kosenko</surname><given-names>E</given-names></name>
</person-group>. <article-title>Specific and pronounced impacts of lisinopril and lisinopril plus simvastatin on erithrocyte antioxidant enzymes</article-title>. <source>J Clin Pharmacol</source>. <year>2010</year>;<volume>50</volume>:<fpage>180</fpage>-<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr22-0091270010388647">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kosenko</surname><given-names>EA</given-names></name>
<name><surname>Solomadin</surname><given-names>IN</given-names></name>
<name><surname>Kaminsky</surname><given-names>YuG</given-names></name>
</person-group>. <article-title>Effect of the b-amyloid peptide Ab25-35 and fullerene C60 on the activity of enzymes in erythrocytes</article-title>. <source>Russ J Bioorg Chem</source>. <year>2009</year>;<volume>35</volume>:<fpage>157</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr23-0091270010388647">
<label>23.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>JP</given-names></name>
<name><surname>Konarsha</surname><given-names>L.</given-names></name>
<name><surname>Arginase</surname></name>
</person-group>. In: <person-group person-group-type="editor">
<name><surname>Bergmeyer</surname><given-names>HU</given-names></name>
</person-group>, ed. <source>Methods of Enzymatic Analysis</source>. <volume>Vol. 4</volume>. <publisher-loc>Weinheim, Germany</publisher-loc>: <publisher-name>Verlag Chemie</publisher-name>; <year>1984</year>:<fpage>285</fpage>-<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr24-0091270010388647">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giustarini</surname><given-names>D</given-names></name>
<name><surname>Rossi</surname><given-names>R</given-names></name>
<name><surname>Milzani</surname><given-names>A</given-names></name>
<name><surname>Dalle-Donne</surname><given-names>I</given-names></name>
</person-group>. <article-title>Nitrite and nitrate measurement by Griess reagent in human plasma: evaluation of interferences and standardization</article-title>. <source>Methods Enzymol</source>. <year>2008</year>;<volume>440</volume>:<fpage>361</fpage>-<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr25-0091270010388647">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleinbongard</surname><given-names>P</given-names></name>
<name><surname>Rassaf</surname><given-names>T</given-names></name>
<name><surname>Dejam</surname><given-names>A</given-names></name>
<name><surname>Kerber</surname><given-names>S</given-names></name>
<name><surname>Kelm</surname><given-names>M</given-names></name>
</person-group>. <article-title>Griess method for nitrite measurement of aqueous and protein-containing samples</article-title>. <source>Methods Enzymol</source>. <year>2002</year>;<volume>359</volume>:<fpage>158</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr26-0091270010388647">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>HH</given-names></name>
<name><surname>Warner</surname><given-names>TD</given-names></name>
<name><surname>Nakane</surname><given-names>M</given-names></name>
<name><surname>Förstermann</surname><given-names>U</given-names></name>
<name><surname>Murad</surname><given-names>F</given-names></name>
</person-group>. <article-title>Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages</article-title>. <source>Mol Pharmacol</source>. <year>1992</year>;<volume>41</volume>:<fpage>615</fpage>-<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr27-0091270010388647">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>CR</given-names></name>
</person-group>. <article-title>New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy</article-title>. <source>Treat Respir Med</source>. <year>2006</year>;<volume>5</volume>:<fpage>31</fpage>-<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr28-0091270010388647">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van de Poll</surname><given-names>MC</given-names></name>
<name><surname>Hanssen</surname><given-names>SJ</given-names></name>
<name><surname>Berbée</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Elevated plasma arginase-1 does not affect plasma arginine in patients undergoing liver resection</article-title>. <source>Clin Sci (Lond)</source>. <year>2008</year>;<volume>114</volume>:<fpage>231</fpage>-<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr29-0091270010388647">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moshage</surname><given-names>H</given-names></name>
<name><surname>Kok</surname><given-names>B</given-names></name>
<name><surname>Huizenga</surname><given-names>JR</given-names></name>
<name><surname>Jansen</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Nitrite and nitrate determinations in plasma: a critical evaluation</article-title>. <source>Clin Chem</source>. <year>1995</year>;<volume>41</volume>(<issue>pt 1</issue>):<fpage>892</fpage>-<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr30-0091270010388647">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guevara</surname><given-names>I</given-names></name>
<name><surname>Iwanejko</surname><given-names>J</given-names></name>
<name><surname>Dembińska-Kieć</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Determination of nitrite/nitrate in human biological material by the simple Griess reaction</article-title>. <source>Clin Chim Acta</source>. <year>1998</year>;<volume>274</volume>:<fpage>177</fpage>-<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr31-0091270010388647">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bloomer</surname><given-names>RJ</given-names></name>
<name><surname>Farney</surname><given-names>TM</given-names></name>
<name><surname>Trepanowski</surname><given-names>JF</given-names></name>
<name><surname>McCarthy</surname><given-names>CG</given-names></name>
<name><surname>Canale</surname><given-names>RE</given-names></name>
<name><surname>Schilling</surname><given-names>BK</given-names></name>
</person-group>. <article-title>Comparison of pre-workout nitric oxide stimulating dietary supplements on skeletal muscle oxygen saturation, blood nitrate/nitrite, lipid peroxidation, and upper body exercise performance in resistance trained men</article-title>. <source>J Int Soc Sports Nutr</source>. <year>2010</year>;<volume>7</volume>:<fpage>16</fpage>.</citation>
</ref>
<ref id="bibr32-0091270010388647">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>J</given-names></name>
<name><surname>Rouleau</surname><given-names>L</given-names></name>
<name><surname>Tardif</surname><given-names>JC</given-names></name>
<name><surname>Leask</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress</article-title>. <source>Life Sci</source>. <year>2010</year>;<volume>87</volume>:<fpage>92</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr33-0091270010388647">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feron</surname><given-names>O</given-names></name>
<name><surname>Dessy</surname><given-names>C</given-names></name>
<name><surname>Desager</surname><given-names>JP</given-names></name>
<name><surname>Balligand</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>113</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr34-0091270010388647">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Himeno</surname><given-names>M</given-names></name>
<name><surname>Ishibashi</surname><given-names>T</given-names></name>
<name><surname>Nakano</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Implication of steady state concentrations of nitrite and nitrate metabolites of nitric oxide in plasma and whole blood in healthy human subjects</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>2004</year>;<volume>31</volume>:<fpage>591</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr35-0091270010388647">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishibashi</surname><given-names>T</given-names></name>
<name><surname>Kubota</surname><given-names>K</given-names></name>
<name><surname>Himeno</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Respiratory alkalosis does not alter NOx concentrations in human plasma and erythrocytes</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2001</year>;<volume>281</volume>:<fpage>H2757</fpage>-<lpage>H2761</lpage>.</citation>
</ref>
<ref id="bibr36-0091270010388647">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bagnost</surname><given-names>T</given-names></name>
<name><surname>Ma</surname><given-names>L</given-names></name>
<name><surname>da Silva</surname><given-names>RF</given-names></name>
<etal/></person-group>. <article-title>Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension</article-title>. <source>Cardiovasc Res</source>. <year>2010</year>;<volume>87</volume>:<fpage>569</fpage>-<lpage>577</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>